This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Post-exercise Insulin Reductions in Type 1 Diabetes

This study has been completed.
Diabetes UK
Information provided by (Responsible Party):
Northumbria University Identifier:
First received: February 7, 2012
Last updated: August 1, 2014
Last verified: August 2014
The investigators hypothesise that reducing rapid-acting insulin dose after exercise will help prevent Type 1 diabetes individuals experiencing hypoglycaemia.

Condition Intervention
Type 1 Diabetes Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Metabolic and Glycaemic Responses to Reductions in Rapid-acting Insulin Dose After Running Exercise in People With Type 1 Diabetes Mellitus.

Resource links provided by NLM:

Further study details as provided by Northumbria University:

Primary Outcome Measures:
  • 24 hour blood glucose area under the curve [ Time Frame: 24 hours ]
    24 hour, post-exercise, glucose area under the curve.

Secondary Outcome Measures:
  • Ketogenesis [ Time Frame: 60 minutes before and 24 hours post-exercise ]
    Blood beta-hydroxybutyrate concentrations

Enrollment: 13
Study Start Date: February 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Insulin dose
Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
Dosage after exercise


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • T1DM,
  • Male,
  • basal-bolus regimen (insulin glargine / detemir with insulin lispro / aspart),
  • HbA1c < 9.9%,
  • aged 18-50.

Exclusion Criteria:

  • HbA1c > 10%,
  • not treated with basal-bolus (insulin glargine / detemir with insulin lispro / aspart),
  • aged <18 > 50.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01531855

United Kingdom
Clinical Research Facility
Newcaslte upon Tyne, Tyne and Wear, United Kingdom, NE1 4LP
Sponsors and Collaborators
Northumbria University
Diabetes UK
Principal Investigator: Daniel J West Northumbria University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Northumbria University Identifier: NCT01531855     History of Changes
Other Study ID Numbers: west-walker1
Study First Received: February 7, 2012
Last Updated: August 1, 2014

Keywords provided by Northumbria University:
T1DM, Exercise

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin Lispro
Insulin, Short-Acting
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017